NXGLW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NX

Volume

66.74K

Loading chart

NX

NXGLWNexGel, Inc Warrant

NXGLW

Pay with—

Available Balance0.00

NX

Mkt Cap

N/A

Volume

66.74K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ETNEXGEL, Inc. has moved up its shareholder update conference call from April 23rd to April 21st, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. The call will be available via phone and webcast for investors seeking updates on the transaction.GlobeNewswire Inc. · Apr 17, 2026

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple RevenueNexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focused on tendon repair, skin grafts, and bone growth with over a decade of clinical use and existing insurance reimbursement pathways.Benzinga · Mar 10, 2026

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRxNEXGEL has created a spin-off company, NexGelRx, to focus exclusively on developing prescription drug delivery solutions using its proprietary hydrogel technology. NEXGEL will retain a 19.99% non-dilutive equity stake and receive a 5% perpetual global royalty.GlobeNewswire Inc. · Dec 11, 2025

NEXGEL (NXGL) Q3 2025 Earnings Call TranscriptNEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.The Motley Fool · Nov 11, 2025

NEXGEL to Report First Quarter 2025 Financial Results on May 13thNEXGEL, Inc. announced it will report its financial results for the first quarter of 2025 on May 13, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.GlobeNewswire Inc. · May 9, 2025

NEXGEL Announces $2,000,000 Registered Direct OfferingNEXGEL, Inc. announced a $2 million registered direct offering, issuing 727,272 shares of common stock and warrants to purchase 363,636 shares. The proceeds will be used to increase inventory, marketing, and support growth.GlobeNewswire Inc. · Nov 11, 2024

NEXGEL Appoints Kip Crecca to its Scientific Advisory BoardNEXGEL, Inc. announced the appointment of Kip Crecca to its Scientific Advisory Board, citing his wealth of knowledge and experience in the medical device sales industry. Crecca will collaborate with NEXGEL's team to support the development of new therapies using the company's hydrogel products.GlobeNewswire Inc. · Oct 4, 2024

Helen of Troy, SMART Global And 3 Stocks To Watch Heading Into Tuesday - Helen Of Troy (NASDAQ:HELE) - BenzingaThe article discusses several stocks to watch heading into Tuesday, including Helen of Troy, NEXGEL, SMART Global Holdings, DigitalOcean, and Kura Sushi USA. It provides details on the expected earnings and revenue for these companies.Benzinga · Jul 9, 2024

NEXGEL projects increased revenue in upcoming quarters - Investing.comNEXGEL, a manufacturer of hydrogel products, reported a 20% year-over-year increase in Q2 2024 revenue and projected significant revenue growth in the next two quarters. The company attributed the strong performance to new partnerships and robust demand for its Silly George brand.Investing.com · Jul 8, 2024

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North AmericaLANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe’s number one selling Diamine Oxidase (‘DAO’) enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin conditions. Headquartered in Germany, STADA is one of the fastest growing top ten companies in consumer healthcare and the fourth largest manufacturer in this segment in Europe.GlobeNewswire Inc. · Jun 11, 2024

to start trading

NX

NXGLWNexGel, Inc Warrant

NXGLW

Pay with—

Available Balance0.00

Your PositionYou don't own any NXGLW yet.

Related Tickers

Earnings